Antibodies to a YYX epitope of a mammalian prion protein

Details Antibodies to a YYX epitope of a mammalian prion protein Antibodies to a YYX epitope of a mammalian prion protein

2006-05-09

2006-05-09

Winkler, Ulrike (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C424S130100, C435S007100, C530S388100, C530S389100

Reexamination Certificate

active

07041807

ABSTRACT:
In general, the invention features antibodies specific for PrPScand diagnostic, therapeutic, and decontamination uses thereof. The invention also features synthetic peptides useful as immunogens for generating antibodies specific for PrPScand therapeutic for the treatment of prion diseases.

REFERENCES:
patent: 4806627 (1989-02-01), Wisniewski et al.
patent: 5597725 (1997-01-01), Suzuki
patent: 5639634 (1997-06-01), Suzuki
patent: 5643781 (1997-07-01), Suzuki
patent: 5646250 (1997-07-01), Suzuki
patent: 5663300 (1997-09-01), Suzuki
patent: 5679530 (1997-10-01), Brentani et al.
patent: 5708143 (1998-01-01), Suzuki
patent: 5750361 (1998-05-01), Prusiner et al.
patent: 5773572 (1998-06-01), Fishleigh et al.
patent: 5798224 (1998-08-01), Suzuki
patent: 5846533 (1998-12-01), Prusiner et al.
patent: 5891641 (1999-04-01), Prusiner et al.
patent: 5891706 (1999-04-01), Suzuki
patent: 6150172 (2000-11-01), Schmerr et al.
patent: 6261790 (2001-07-01), O'Rourke
patent: 6290954 (2001-09-01), Prusiner et al.
patent: 6372214 (2002-04-01), Prusiner et al.
patent: 6462171 (2002-10-01), Soto-Jara et al.
patent: 197 41 607 (1997-09-01), None
patent: 0 861 900 (1998-09-01), None
patent: 1 213 301 (2002-12-01), None
patent: 1529119 (1989-12-01), None
patent: WO 87/06706 (1987-11-01), None
patent: WO 92/06220 (1992-04-01), None
patent: WO 92/08731 (1992-05-01), None
patent: WO 93/11155 (1993-06-01), None
patent: WO 93/23432 (1993-11-01), None
patent: WO 94/01116 (1994-01-01), None
patent: WO 96/32128 (1996-10-01), None
patent: 96/39834 (1996-12-01), None
patent: WO 97/10505 (1997-03-01), None
patent: WO 97/16728 (1997-05-01), None
patent: WO 97/43649 (1997-11-01), None
patent: WO 97/45746 (1997-12-01), None
patent: WO 98/37210 (1998-08-01), None
patent: WO 99/15651 (1999-04-01), None
patent: WO 99/19360 (1999-04-01), None
patent: WO 99/42829 (1999-08-01), None
patent: WO 99/66956 (1999-12-01), None
patent: WO 00/78344 (2000-12-01), None
patent: WO 01/00235 (2001-01-01), None
patent: WO 04/029072 (2004-04-01), None
Harlow et al., Antibodies: a laboratory manual, Cold Spring Harbor Laboratory (1988) pp. 27-28.
Bolton et al., “Molecular Location of a Species-Specific Epitope on the Hamster Scrapie Agent Protein,”J. Virology65:3667-3675 (1991).
Di Martino et al., “Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-Carrier Linked Synthetic Peptide Immunogens,”J. Molecular Recognition4:85-90 (1991).
Harmeyer et al., “Synthetic Peptide Vaccines Yield Monoclonal Antibodies to Cellular and Pathological Prion Proteins of Ruminants,”J. of General Virology79:937-945 (1998).
Korth et al., “Prion (PrPSc)- Specific Epitope Defined by a Monoclonal Antibody,”Nature390:74-77 (1997).
Schenk et al., “Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse,”Nature400:173-177 (1999).
St. George-Hyslop et al., “Antibody Clears Senile Plaques,”Nature400:116-117 (1999).
Bolton et al., “Identification of a Protein That Purifies with the Scrapie Prion,”Science218:1309-1311 (1982).
Brown et al., “Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans,”Transfusion39:1169-1178 (1999).
Brown et al., “The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy,”Transfusion38:810-816 (1998).
Cioni, “Oxygen and acrylamide quenching of protein phosphorescence: correlation with protein dynamics,”Biophysical Chemistry87:15-24 (2000).
Cohen et al., “Pathologic Conformations of Prion Proteins,”Annu. Rev. Biochem.67:793-819 (1998).
Donne et al., “Structure of the recombinant full-length hamster prion protein PrP(29-231): The N terminus is highly flexible,”Proc. Natl. Acad. Sci. USA94:13452-13457 (1997).
Fischer et al., “Binding of disease-associated prion protein to plasminogen,”Nature408:479-483 (2000).
Hornemann et al., “A scrapie-like unfolding intermediate of the prion protein domain PrP(121-232) induced by acidic pH,”Proc. Natl. Acad. Sci. USA95:6010-6014 (1998).
Jackson et al., “Reversible Conversion of Monomeric Human Prion Protein Between Native and Fibrilogenic Conformations,”Science283:1935-1937 (1999).
Kascsak et al., “Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins,”Journal of Virology61:3688-3692 (1987).
Korth et al., “Monoclonal Antibodies Specific for the Native, Disease-Associated Isoform of the Prion Protein,”Methods in Enzymology309:106-122 (1999).
Korth et al., “Prion (PrPSc)-specific epitope defined by a monoclonal antibody,”Nature390:74-77 (1997).
Kondejewski et al., “Dissociation of Antimicrobial and Hemolytic Activities in Cyclic Peptide Diastereomers by Systematic Alterations in Amphipathicity,”J. Biol. Chem.274:13181-13192 (1999).
McGaughey et al., “π-Stacking Interactions. Alive and Well in Proteins,”J. Biol. Chem.273:15458-15463 (1998).
Pan et al., “Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins,”Proc. Natl. Acad. Sci. USA90:10962-10966 (1993).
Pergami et al., “Semipreparative Chromatographic Method to Purify the Normal Cellular Isoform of the Prion Protein in Nondenatured Form,”Analytical Biochemistry236:63-73 (1996).
Prusiner “Novel Proteinaceous Infectious Particles Cause Scrapie,”Science216:136-144 (1982).
Prusiner “Prions,”Proc. Natl. Acad. Sci. USA95:13363-13383 (1998).
Riek et al., “NMR structure of the mouse prion protein domain PrP(121-231),”Nature382:180-182 (1996).
Safar et al., “Eight prion strains have PrPScmolecules with different conformations,”Nature Medicine4:1157-1165 (1998).
Swietnicki et al., “pH-dependent Stability and Conformation of the Recombinant Human Prion Protein PrP(90-231),”Journal of Biological Chemistry272:27517-27520 (1997).
Williamson et al., “Mapping the Prion Protein Using Recombinant Antibodies,”Journal of Virology72:9413-9418 (1998).
Zahn et al., “NMR solution structure of the prion protein,”Proc. Natl. Acad. Sci. USA97:145-150 (2000).
Fischer et al., “Prion Protein (PrP) with Amino-Proximal Deletions Restoring Susceptibility of PrP Knockout Mice to Scrapie”,EMBO Journal.15:1255-1264 (1996).
Heppner et al., “Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies”,Science,294:178-82 (2001).
Maissen et al., “Plasminogen Binds to Disease-Associated Prion Protein of Multiple Species”,Lancet,357:2026-2028 (2001).
Paramithiotis et al., “A Prion Protein Epitope Selective for the Pathologically Misfolded Conformation”,Nature Medicine,9:893-899 (2003). (Advance Online Publication).
Bacon and Anderson, “Multiple Sequence Alignment,”J. Mol. Biol.191:153-161 (1986).
Bennett et al., “3D Domain Swapping: A Mechanism for Oligomer Assembly,”Protein Science4:2455-2648 (1995).
Bolton and Bendheim, “A Modified Host Protein Model of Scrapie,”Ciba Found. Symp.135:164-181 (1988).
Bradley, “BSE Transmission Studies with Particular Reference to Blood,”Dev. Biol. Stand.99:35-40 (1999).
Brown et al., “Iatrogenic Creutzfeldt-Jakob Disease at the Millennium,”Neurology55:1075-1081 (2000).
Büeler et al., “Mice Devoid of PrP are Resistant to Scrapie,”Cell73:1339-1347 (1993).
Büeler et al., “Normal Development and Behaviour of Mice Lacking the Neuronal Cell-Surface PrP Protein,”Nature356:577-582 (1992).
Cashman, “A Prion Primer,”CMAJ157:1381-1385 (1997).
Cashman et al., “A Prion-Specific

Affiliated with

Also associated with

Rating

Antibodies to a YYX epitope of a mammalian prion protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to a YYX epitope of a mammalian prion protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to a YYX epitope of a mammalian prion protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3623055